The SARS-CoV-2 pandemic and asthma: What we have learned and what is still unknown

Christa McPhee, Kateryna Yevdokimova, Linda Rogers, Monica Kraft

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations


The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has brought new insights into the immunologic intricacies of asthma. In this review, we discuss the epidemiology of asthma in patients infected with SARS-CoV-2 and the risk of severe infection. Type 2 inflammation had an overall protective effect against SARS-CoV-2 infection by various mechanisms summarized in this review. Asthma, intranasal, and inhaled corticosteroids decreased the angiotensin-converting enzyme 2 receptor, an important receptor for SARS-CoV-2 entry into host cells. We summarize the nuances of the treatment of type 2 inflammation despite its underlying protective effects. Research to date has shown that patients on various allergen immunotherapies and biologics do benefit from being vaccinated.

Original languageEnglish (US)
Pages (from-to)1376-1381
Number of pages6
JournalJournal of Allergy and Clinical Immunology
Issue number6
StatePublished - Dec 2023
Externally publishedYes


  • ACE2 receptor
  • Asthma
  • COVID-19
  • allergen immunotherapy
  • antiviral mechanisms
  • biologic
  • exacerbations
  • immunophenotyping assessment of COVID-19
  • type 2 inflammation
  • vaccine

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'The SARS-CoV-2 pandemic and asthma: What we have learned and what is still unknown'. Together they form a unique fingerprint.

Cite this